title: Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis.
abstract: BACKGROUND
  We performed a randomized, double-blind, prospective, 16-week clinical trial to evaluate the efficacy and safety of risedronate with and without cholecalciferol on 25-hydroxyvitamin D [25(OH)D] levels and bone markers in Korean patients with osteoporosis.
  
  
  METHODS
  We randomly assigned 164 adults with osteoporosis to one of two treatment groups: weekly risedronate 35 mg and cholecalciferol 5600 IU combined in a single pill (RSD+) or weekly risedronate 35 mg alone (RSD). We measured serum levels of 25(OH)D, parathyroid hormone (PTH), and bone markers and performed muscle function tests, at baseline and after 16 weeks of treatment.
  
  
  RESULTS
  After 16 weeks of treatment, mean serum 25(OH)D increased significantly from 39·8 to 70·8 nmol/l in the RSD+ group and declined significantly from 40·5 to 35 nmol/l in the RSD group. Although both treatment groups had significant increases in serum PTH over baseline during the study, the RSD group had a significantly larger increase than the RSD+ group (13·6 vs 4·8 ng/l; P = 0·0005). In both groups, serum bone-specific alkaline phosphatase (BSAP) and C-terminal telopeptide (CTX) declined rapidly; there were no significant differences between groups. There was also no significant difference between groups in lower-extremity function tests. The overall incidence of clinical adverse events was not significantly different between groups.
  
  
  CONCLUSIONS
  In patients with osteoporosis, a once-weekly pill of risedronate and cholecalciferol provided equivalent antiresorptive efficacy to risedronate alone in terms of bone turnover and improved 25(OH)D level over a 16-week treatment period without significant adverse events.
authors.affiliation: Kyung Hee University, Seoul, Korea.
authors.forename: Ho-Yeon
authors.initials: HY
authors.lastname: Chung
authors.forename: Sang Ouk
authors.initials: SO
authors.lastname: Chin
authors.forename: Moo-I L
authors.initials: MI
authors.lastname: Kang
authors.forename: Jung-Min
authors.initials: JM
authors.lastname: Koh
authors.forename: Sung-Hwan
authors.initials: SH
authors.lastname: Moon
authors.forename: Byung-Koo
authors.initials: BK
authors.lastname: Yoon
authors.forename: Hyun-Koo
authors.initials: HK
authors.lastname: Yoon
authors.forename: Yoon-Sok
authors.initials: YS
authors.lastname: Chung
authors.forename: Hyoung-Moo
authors.initials: HM
authors.lastname: Park
mesh_terms: D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D044466:Asian People; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use; D002762:Cholecalciferol / Q000009:adverse effects / Q000627:therapeutic use*; D024042:Collagen Type I / Q000097:blood; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D012968:Etidronic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D007723:Korea; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000097:blood / Q000188:drug therapy* / Q000208:ethnology; D015663:Osteoporosis, Postmenopausal / Q000097:blood / Q000188:drug therapy / Q000208:ethnology; D010281:Parathyroid Hormone / Q000097:blood; D010455:Peptides / Q000097:blood; D011446:Prospective Studies; D011863:Radioimmunoassay; D000068296:Risedronic Acid; D016896:Treatment Outcome; D014807:Vitamin D / Q000031:analogs & derivatives* / Q000097:blood
chemical_list: D050071:Bone Density Conservation Agents; D024042:Collagen Type I; D010281:Parathyroid Hormone; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D014807:Vitamin D; D002762:Cholecalciferol; C104450:25-hydroxyvitamin D; D000469:Alkaline Phosphatase; D000068296:Risedronic Acid; D012968:Etidronic Acid